May 2nd - 6th, 2022 | Hynes Convention Center
Applied BioMath Presence
Presentation: De-risking Bispecifics Early-on: How tight is too tight? How weak is too weak?
Presenter: John Burke, PhD, Co-Founder, President and CEO
Presentation Time: Friday, May 6th, at 10:00 a.m.
Bispecifics are exciting due to their improved specificity, additional MOA, and/or improved therapeutic index. They may be more risky due to increased development complexity, experiment combinatorics, cost and time. Here a T-Cell engager case study is used to highlight Applied BioMath Assess, a web enabled model informed drug development and discovery analysis application, that helps quickly generate actionable hypotheses, impacting critical thinking and portfolio decisions, thus derisking projects.
Presentation: A Systems Model of Gene Therapy for Sickle Cell Disease
Presenter: Raibatak Das, PhD, Principal Scientist, Applied BioMath
Presentation Time: Thursday, May 5th, at 9:30 a.m.
Sickle cell disease (SCD) is an inherited genetic disease of the blood with no known cure. Stem cell gene therapy is an emerging experimental therapy for SCD with the potential for lifelong cure, but it is an expensive multi-step treatment regimen. We developed a quantitative systems pharmacology model to predict how varying treatment will affect post-treatment hemoglobin and red blood cell dynamics after autologous stem cell gene therapy.